Company / Accounts Receivable
Tandem Diabetes Care Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$165.5M
FY2025
5-year range
$105.6M / $165.5M
FY2021-FY2025
Trend
+44.4%
vs FY2024
Sector context
#77 of 138
Health Care
What the data says
At $165M, Tandem Diabetes Care's accounts receivable ranks #77 of 138 in the Health Care sector. Improved from $106M to $165M over the past 2 years.
Based on SEC 10-K filings.
$165M in FY2025 with a 5-year CAGR of +15.0%.
Improved from $106M to $165M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +13.0%
- 5-Year CAGR
- +15.0%
- 10-Year CAGR
- -
Sector benchmark
#77 of 138 in Health CareTop 56% of 138This company $165.5M Sector average $1.3B
▼
-87.5% below sector average
Key checks
Key Insights
- 5-year CAGR of +15.0%, indicating consistent growth.
- In FY2025, accounts receivable increased 44.4% year-over-year.
- Ranks #77 out of 138 companies in the Health Care sector.
- Lowest accounts receivable in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -0.32 (distress zone, below 1.8 threshold)
- Negative profit margin: -20.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $165.5M | +44.4% |
| FY2024 | $114.6M | +8.6% |
| FY2023 | $105.6M | -8.0% |
| FY2022 | $114.7M | +3.6% |
| FY2021 | $110.7M | +34.7% |
| FY2020 | $82.2M | +76.4% |
| FY2019 | $46.6M | +32.4% |
| FY2018 | $35.2M | +69.3% |
| FY2017 | $20.8M | +86.1% |
| FY2016 | $11.2M | -20.5% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026